Condition: Primary Membranous Nephropathy · Sponsor: Cerium Pharmaceuticals, Inc.
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
This description comes directly from the study's public registry record.
Nancy Klett, MPH · 703-395-0629 · Nancy.Klett@ceriumpharma.com
Always discuss trial participation with your own doctor first.
| Academic Medical Research Institute | Los Angeles, California, United States | Recruiting |
| North America Research Institute | San Dimas, California, United States | Recruiting |
| Valiance Clinical Research | Tarzana, California, United States | Recruiting |
| RecioMed Clinical Research Network, Inc. | Boynton Beach, Florida, United States | Recruiting |
| South Florida Nephrology Research | Coral Springs, Florida, United States | Recruiting |
| Therafirst Medical Center | Fort Lauderdale, Florida, United States | Recruiting |
| Reliant Medical Research, LLC | Miami, Florida, United States | Recruiting |
| Vista Health Research, LLC | Miami, Florida, United States | Recruiting |
| Genesis Clinical Research | Tampa, Florida, United States | Recruiting |
| Fides Clinical Research | Atlanta, Georgia, United States | Recruiting |
| Costal Medical Research | Brunswick, Georgia, United States | Recruiting |
| Insight Hospital and Medical Center Chicago | Chicago, Illinois, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05696613